Ask AI

From Today to Tomorrow: Iberdomide’s New Approval in Multiple Myeloma and What It Means for Practice

This educational program will review the mechanistic rationale and clinical evidence supporting the newly approved CELMoD iberdomide in multiple myeloma. Expert faculty will examine key efficacy and safety data, the implications of the new approval for the evolving treatment landscape, and considerations for incorporating iberdomide into clinical practice, including patient selection and treatment sequencing.

Program Content

Events

  • Live Event
    From Today to Tomorrow: Iberdomide’s New Approval in Multiple Myeloma and What It Means for Practice
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

No activities added yet